Announcement on Preliminary Earnings Estimate for 2025
Filed with SSE · · 3 pages · Chinese
Shanghai Allist Pharmaceuticals Co. Ltd. on 6ix
Earlier from Shanghai Allist Pharmaceuticals
- Announcement on Voluntary Disclosure of Progress in Drug Registration for Second-Line Treatment of EGFR Exon 20 Insertion Mutation NSCLC in the Priority Review Process
- Announcement on Expected Increase in Performance for 2025
- Announcement on Voluntary Disclosure of Inclusion of Furmonertinib Mesylate Tablets for EGFR PACC-mutant NSCLC First-line Treatment in the Proposed Breakthrough Therapy Designation
- Announcement on Using Partial Temporarily Idle Raised Funds for Cash Management
- Announcement on Voluntary Disclosure of the Inclusion of the Company’s Innovative Drugs in the Updated National Medical Insurance Catalog
Later from Shanghai Allist Pharmaceuticals
- Announcement on Voluntary Disclosure of Earnings Preannouncement for Q1 2026
- Announcement on Convening Performance and Cash Dividend Briefing for 2025 and Q1 2026
- Notice on Convening the 2025 Annual General Meeting
- Announcement on Voluntary Disclosure of Obtaining of Approval Notice for the Drug Clinical Trial of Newly Approved Indication of Furmonertinib Mesylate Tablets
- Announcement on Resolutions of the 2025 Annual General Meeting
Follow Shanghai Allist Pharmaceuticals into a list and get an email when it puts out news.
Follow Shanghai Allist Pharmaceuticals